ABU DHABI, UAE, Oct. 13, 2023 /PRNewswire/ — M42, a global technology-enabled healthcare network, has introduced an impactful breakthrough in healthcare technology with the launch of Med42, a new clinical model of open access large language (LLM). The 70 billion-parameter generative artificial intelligence (AI) model is poised to transform the future of AI across healthcare and create a direct impact on patient care outcomes.
Med42 provides high-quality answers to short and long medical questions. The model has been developed to exponentially improve clinical decision making and increase access to synthesized medical knowledge for healthcare professionals, patients and medical researchers through to regulators.
Med42 was trained using M42’s industry-leading curated medical knowledge dataset. When tested on multiple healthcare-relevant data sets, the model outperforms larger closed models, such as ChatGPT 3.5, and achieves a score of 72%, on a zero assessment, on the Exam sample exam questions. of the United States Medical License (USMLE).
Developed by the Abu Dhabi-based M42 team, Med42 was trained and refined with Cerebras in collaboration with Core42, a G42 company focused on enabling the delivery of enterprise AI and AI programs on a national scale. A team from the Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) further evaluated the model’s accuracy.
Hasan Jasem Al Nowais, President and CEO of M42 Group, said: “Med42 will accelerate global access to healthcare knowledge and embodies our commitment to achieving transformative impact across the healthcare sector. M42 is pushing the boundaries of innovation and graphics in healthcare – a path to more personalized, patient-centric care – M42’s unique combination of world-class healthcare expertise and cutting-edge medical technologies allows us to impactfully contribute to the future of AI in healthcare: a future where AI is accessible to everyone while being rooted in ethics and prioritizing user safety.”
Al Nowais continued: “The launch of Med42 firmly establishes and demonstrates the UAE’s prominent position in the global generative AI space. We appreciate the support of the Abu Dhabi Department of Health and Abu Dhabi’s broader technology ecosystem.”
Med42 has the potential to revolutionize the pace of clinical decision-making, acting as an AI assistant for healthcare professionals. The model’s capability extends to developing personalized treatment plans by analyzing a patient’s medical history to identify the best course of treatment. Other use cases include helping doctors access information faster, helping pharmacists decide correct dosages, and supporting scientists studying treatment options to review the literature efficiently.
To further promote collaboration and improvement of the generative AI model, Med42 is available for download on Hugging Face, enabling widespread testing, review, and evaluation by the scientific and developer community. Licensed on similar terms to Meta’s Llama 2 model, Med42 is free for non-commercial use and research, with appropriate usage controls, given the obvious risks that could arise when implementing AI in a healthcare context.
Ashish Koshy, COO of M42 Group, emphasized: “Innovation is not just about leading technologies. It is about delivering impactful and secure solutions to real-world challenges. Med42 is not just a tool; it is a platform for collaboration. M42 aims to catalyze global innovation in AI for healthcare, training experts from around the world to refine and expand the model’s applications in various medical domains. Our partnerships with technology leaders, including Cerebras, allow us to make it a reality this vision and achieve our long-term transformative goals.
Full parameter tuning of the larger Llama 2 model was successfully achieved on Cerebras and G42’s Condor Galaxy 1 (CG-1) artificial intelligence supercomputer. The rapid setup and reduced training time were made possible by the 82 terabytes of memory and 54 million AI cores in the 64 Cerebras CS-2 systems within the CG-1.
Andrew Feldman, co-founder and CEO of Cerebras Systems, said: “Our strategic partnership with G42 and its portfolio companies is designed to change the AI landscape. Our collaboration has already delivered Condor Galaxy 1, the largest AI supercomputer in the world. world, as well as Jais, the leading Arab LLM, to the community. Today, we help bring another cutting-edge LLM to the world, Med42, with enormous benefits to the healthcare landscape.”
M42 is uniquely positioned to lead the transformation of the healthcare industry due to its unparalleled access to medical and data-centric technologies, including genomics and artificial intelligence, along with its broad portfolio of world-class patient services and its state-of-the-art service network. State-of-the-art facilities to provide the highest level of personalized, precise and preventive care.
About M42
M42 is a global technology-based healthcare company based in Abu Dhabi that is at the forefront of medical advancement. The company seeks to transform lives through innovative clinical solutions that can solve the world’s most critical health and diagnostic challenges. By leveraging innovative solutions and unique medical and data-centric technologies, including genomics and artificial intelligence, M42 is impactfully transforming the traditional healthcare ecosystem and delivering the highest level of preventive, accurate and patient-centered care.
M42 has more than 20,000 employees and more than 450 facilities in 25 countries. Established in 2022, following the merger of G42 Healthcare and Mubadala Health, M42 is a first-of-its-kind integrated healthcare company that combines unique medical and data-centric technologies with state-of-the-art facilities to deliver world-class services.
www.m42.ae
Contact:
Halima IslamDirectora de cuentasHill Knowlton Strategies 971 52 302 0784
Logo – https://mma.prnewswire.com/media/2245700…
View original content: https://www.prnewswire.com/news-releases/m42-anuncia-un-nuevo-llm-clinico-para-transformar-el-futuro-de-la-ia-en-la-atencion-medica-301956483.html
